To assess whether APOE4 reduction provides neuroprotection to plaque- and CAA-associated neural processes, we assessed neuritic dystrophy by labeling for LAMP1, a lysosomal marker that is highly enriched in large, swollen axons surrounding amyloid and CAA [59, 60]. The gene discussed is LAMP1; the disease is amyloidosis.